Lilly Lifts Outlook Again as Zepbound Sales Surge

Eli Lilly has raised its financial outlook for the third time this year, a sign that demand for Zepbound is running ahead of the company's earlier expectations.

Zepbound continues to dominate the market for prescription weight-loss drugs in the United States. The injection belongs to the GLP-1 class of medicines, which has reshaped the obesity treatment market over the past few years and drawn in patients, doctors, and investors alike.

Repeated guidance increases tell investors that the company sees its core product gaining ground rather than leveling off. For a stock that has been closely tied to the GLP-1 story, that kind of momentum matters. Forecasts of this kind can still shift with pricing, supply, and competition, so the next earnings report will show whether the trend holds.